These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Baronti F; Mouradian MM; Davis TL; Giuffra M; Brughitta G; Conant KE; Chase TN Ann Neurol; 1992 Dec; 32(6):776-81. PubMed ID: 1471868 [TBL] [Abstract][Full Text] [Related]
27. Further studies with lisuride in Parkinson's disease. Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E Eur Neurol; 1983; 22(2):119-23. PubMed ID: 6341071 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease. Capria A; Attanasio A; Quatrana M; Cannata D; Fioravanti M; Stocchi F; Ruggieri S Clin Neuropharmacol; 1989 Aug; 12(4):331-8. PubMed ID: 2804995 [TBL] [Abstract][Full Text] [Related]
29. [Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy]. Rinne UK Nervenarzt; 1999 Jan; 70 Suppl 1():S19-25. PubMed ID: 10087526 [TBL] [Abstract][Full Text] [Related]
30. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa. Lieberman A; Goldstein M; Neophytides A; Kupersmith M; Leibowitz M; Zasorin N; Walker R; Kleinberg D Neurology; 1981 Aug; 31(8):961-5. PubMed ID: 7022259 [TBL] [Abstract][Full Text] [Related]
31. Comparison between L-dopa and lisuride intravenous infusions: a clinical study. Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176 [TBL] [Abstract][Full Text] [Related]
33. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
34. [Oral lisuride in Parkinson's disease]. Obeso JA; Luquin MR; Martínez Lage JM Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822 [No Abstract] [Full Text] [Related]
35. A study on the effect and tolerance of lisuride on Parkinson's disease. Bayülkem K; Erişir K; Tuncel A; Bayülkem B Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174 [TBL] [Abstract][Full Text] [Related]
37. Use of ergot derivative lisuride in Parkinson's disease. Suchy I; Horowski R Adv Neurol; 1984; 40():515-21. PubMed ID: 6695629 [No Abstract] [Full Text] [Related]
38. Bromocriptine and lisuride in Parkinson disease. Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Walker R; Hiesiger E Ann Neurol; 1983 Jan; 13(1):44-7. PubMed ID: 6830164 [TBL] [Abstract][Full Text] [Related]
39. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Rinne UK Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639 [TBL] [Abstract][Full Text] [Related]
40. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist. Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]